Last reviewed · How we verify
NCT04404270: EpiCovCreil
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)
trial testing Anti-SARS-CoV2 Serology in Sars-CoV2 in 1,146 participants. Completed in 13 March 2021.
13 March 2021
Quick facts
| Lead sponsor | Direction Centrale du Service de Santé des Armées |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,146 |
| Start date | 26 May 2020 |
| Primary completion | 13 March 2021 |
| Estimated completion | 13 March 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Anti-SARS-CoV2 Serology
- Questionnaire
- Anti-SARS-CoV2 serological controls and serum neutralization
Conditions studied
- Sars-CoV2 — all drugs for Sars-CoV2 →
Sponsor
Direction Centrale du Service de Santé des Armées — full company profile →
Who can join
18 and older, any sex, with Sars-CoV2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04404270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-SARS-CoV2 Serology
Trials testing the same drug.
- NCT04816084 — SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes · NA · completed
- NCT04516928 — Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel · completed
- NCT04387838 — Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff · completed
Other recruiting trials for Sars-CoV2
Currently open trials in the same condition.
- NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
- NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
- NCT04363853 — Tocilizumab Treatment in Patients With COVID-19 · Phase 2 · active not recruiting
- NCT04424992 — The Natural History of Hospitalized COVID-19 Patients · recruiting
Other Direction Centrale du Service de Santé des Armées trials
Trials by the same sponsor.
- NCT07352904 — Exploration Strategies in Night Vision Sensors · not yet recruiting
- NCT07344493 — Average ANKLE GO Score in the Objective Functional Assessment of the Ankle in Healthy Military Personnel (ANKMIL) · completed
- NCT06996275 — Attachment and Post-Traumatic Stress Disorder in Military Personnel: Characterization of the French Military Population, · not yet recruiting
- NCT06490029 — Diagnostic of Various Ototoxicity Induced by Cancer Treatment · recruiting
- NCT06174181 — Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degenerat · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04404270 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Direction Centrale du Service de Santé des Armées
- Last refreshed: 7 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04404270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing